| Parasitoses intestinais: uma revisão sobre seus aspectos sociais, epidemiológicos, clínicos e terapêuticos. EC de Andrade, ICG Leite, V de Oliveira Rodrigues, MG Cesca Revista de APS 13 (2), 2010 | 276 | 2010 |
| HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer L de Moura Leite, MG Cesca, MC Tavares, DM Santana, EF Saldanha, ... Breast cancer research and treatment 190 (1), 155-163, 2021 | 97 | 2021 |
| HER2-positive advanced breast cancer treatment in 2020 MG Cesca, L Vian, S Cristóvão-Ferreira, N Pondé, E de Azambuja Cancer treatment reviews 88, 102033, 2020 | 92 | 2020 |
| Factors associated with lymphedema in patients with breast cancer DMF Paiva, ICG Leite, VO Rodrigues, MG Cesca Rev Bras Ginecol Obstet 33, 75-80, 2011 | 42* | 2011 |
| Prevalence of lymphedema in women undergoing treatment for breast cancer in a referral center in southeastern Brazil DMF Paiva, VO Rodrigues, MG Cesca, PV Palma, ICG Leite BMC women's health 13, 1-7, 2013 | 27 | 2013 |
| Voice analysis after cancer treatment with organ preservation RJDS Campos, CTV Maciel, MG Cesca, ICG Leite Head & neck oncology 3, 1-5, 2011 | 21 | 2011 |
| Combined endocrine and targeted therapy in luminal breast cancer M Goldner, N Pandolfi, D Maciel, J Lima, S Sanches, N Pondé Expert review of anticancer therapy 21 (11), 1237-1251, 2021 | 16 | 2021 |
| Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis AABA da Costa, ES Dos Santos, DP Cotrim, NC Pandolfi, MG Cesca, ... BMC cancer 19, 1-8, 2019 | 5 | 2019 |
| Comparison of enzalutamide versus abiraterone in castration-resistant prostate cancer before docetaxel: Results of a propensity score-matched analysis. MG Cesca, MT Silveira, NC Pandolfi, TB Oliveira, JA Rinck, ... Journal of Clinical Oncology 37 (15_suppl), e16540-e16540, 2019 | 4 | 2019 |
| Influence of proton pump inhibitors on the pathological response of rectal cancer: a multicentre study MG Cesca, E Ruiz-Garcia, R Weschenfelder, N D’Agustini, S Iseas, ... ecancermedicalscience 17, 2023 | 3 | 2023 |
| Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients F Pignataro-Oshiro, AB Figueiredo, NAL Galdino, KLP Morais, WO Dutra, ... Frontiers in immunology 13, 1052104, 2023 | 1 | 2023 |
| HER2-low and gastric cancer: A prognostic biomarker? BCM Uchôa, R Pirolli, LB Mendes Gomes Siqueira, FGR Moura, ... Journal of Clinical Oncology 39 (15_suppl), e16086-e16086, 2021 | 1 | 2021 |
| Abstract PS4-40: Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer BRS Mattos, MG Cesca, L de Moura Leite, MC Tavares, SF Silva, R Pirolli, ... Cancer Research 81 (4_Supplement), PS4-40-PS4-40, 2021 | 1 | 2021 |
| 256P Risk of CNS metastasis after neoadjuvant chemotherapy: Pathological complete response may not be enough SK Loose, MC Tavares, LDM Leite, MG Cesca, PD Andrade, ... Annals of Oncology 31, S342, 2020 | 1 | 2020 |
| Solitary fibrous tumor: A Brazilian cohort analysis. MG Cesca, CL Mello, T Felismino, MN Formiga, UR Nicolau, S Aguiar, ... Journal of Clinical Oncology 37 (15_suppl), 11068-11068, 2019 | 1 | 2019 |
| Abstract PO3-03-06: Real-world efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in Brazilian patients with early-stage triple-negative breast cancer isadora sousa, ACM Comini, I BORGES, FC Balint, L Martins, DG Sousa, ... Cancer Research 84 (9_Supplement), PO3-03-06-PO3-03-06, 2024 | | 2024 |
| Abstract PO5-02-14: Clinical-pathological determinant factors to choose between four or six cycles of adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) in a … M Kraychete, M Cesca, G Almeida, L Santana, L Leite, SM Sanches, ... Cancer Research 84 (9_Supplement), PO5-02-14-PO5-02-14, 2024 | | 2024 |
| Abstract PO2-16-07: Real-world eligibility for adjuvant CDK4/6 inhibitors among patients without genomic risk for chemotherapy: a GBECAM multicenter retrospective study L Oliveira, T Megid, D Rosa, D Assad-Suzuki, D Argolo, S Sanches, ... Cancer Research 84 (9_Supplement), PO2-16-07-PO2-16-07, 2024 | | 2024 |
| Abstract PO3-17-11: The Utility of Oncotype DX in Grade 1 Hormone Receptor-Positive Early Breast Cancer: Insights from a Multicentric Real-World Data Study RC Bonadio, L Oliveira, D Batista, D Rosa, A Katz, M Mano, ... Cancer Research 84 (9_Supplement), PO3-17-11-PO3-17-11, 2024 | | 2024 |
| Loss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer ÁMC Caldas, WA Nunes, R Taboada, MG Cesca, JN Germano, ... | | 2024 |
Solange Moraes SanchesMédica Titular do Depto de Oncologia Clinica do Hospital AC CamargoVerified email at accamargo.org.br
